Background: Escherichia coli and Klebsiella pneumoniae clinical isolates producing CTX-M extendedspectrum β-lactamases (ESBLs) were assessed for antimicrobial resistance phenotypes varied by group of enzymes. Methods: A total of 1,338 blood isolates, including 959 E. coli and 379 K. pneumoniae, were studied. All the strains were collected between January and July 2017 from eight general hospitals in South Korea. The species were identified by matrix-assisted laser desorption ionization-time of flight mass spectrometry. Antimicrobial susceptibilities were determined by disk diffusion methods and ESBL phenotypes by double-disk synergy tests using disks containing cefotaxime, ceftazidime, cefepime, aztreonam, and clavulanic acid (CA). The genes for β-lactamases were identified by PCR and sequencing. Results: Of total microbes, 31.6% (303/959) E. coli and 24.0% (91/379) K. pneumoniae were resistant to cefotaxime and 28.1% (269/959) E. coli and 20.1% (76/379) K. pneumoniae were CTX-M-type ESBL producers. Among the detected CTX-M ESBLs, 58.0% (156/269) in E. coli and 86.8% (66/76) in K. pneumoniae belonged to group 1, 46.8% (126/269) in E. coli and 14.5% (11/76) in K. pneumoniae were group 9. Ten E. coli and one K. pneumoniae isolates co-produced both groups of CTX-M ESBL. The group 1 CTX-M producers had a higher level of resistance to cefotaxime, ceftazidime, cefepime, and aztreonam and exhibited stronger synergistic activities when combined with CA compared to group 9. Conclusion: ESBL phenotypes differ by CTX-M ESBL group and phenotype testing with drugs including 4 th generation cephalosporins and monobactams is critical for screening CTX-M-producers with better sensitivity. (Ann Clin Microbiol 2019;22:1-8)
INTRODUCTION
Extended-spectrum cephalosporins are one of the preferred choice for empirical therapy for infections by Gram-negative bacteria. However, dissemination of the extended-spectrum βlactamases (ESBLs) conferring resistance to wide-range of β-lactams including the 3 rd and 4 th generation cephalosporins and monobactams, complicates antimicrobial therapy in the clinical settings [1] .
Among over 10 families of ESBLs documented to date [2] , the plasmid-mediated cefotaximase CTX-M is the most rapidly growing family with a significant clinical impact [3] . The CTX-M ESBL was first identified in Japan [4] and designated in Germany [5] . The growing family consists with heterogeneous groups of enzymes. The amino acid sequence alignment of CTX-M variants categorized the enzymes into five groups, i.e., 1, 2, 8, 9, and 25 , sharing ＞94% amino acid identity within a group and ≤90% amino acid identity between groups [6] . The groups are also differed by the hydrolytic property. The first cefotaximase CTX-M-3, renamed from FEC-1, did not confer resistance to ceftazidime [4] and the following CTX-M variants also confer resistance to cefotaxime. The C7 β-amino thiazol-oxyimino-amide side chain protected the ceftazidime against majority of the CTX-M ESBLs [7] . However, some CTX-M ESBLs, mostly belonging to the group 1, had broader substrate-spectrum including ceftazidime resulting in varied resist- Clavulanic acid (CA) is an effective inhibitor for ESBL including CTX-M, and the combination with amoxicillin and ticarcillin, which are both good substrates for the ESBLs, are used in the clinical settings for the infection treatment [8] . By using this activity, CA is widely used for synergy test to detect ESBL producers in the laboratory [9] . CA induces the AmpC production, which can mask the synergistic effects of cephalosporins with CA by inhibiting ESBLs when a bacterial host carries both an ESBL and an AmpC [10] .
The differed activity and spectrum between the groups of CTX-M ESBLs are empirical facts, however the phenotypic differences are indeed controversial. Thereby, this study was designed to evaluate the differences in resistance phenotypes by the group of CTX-M ESBLs.
MATERIALS AND METHODS

Bacterial strains
Non-duplicate 1,338 blood isolates including 959 E. coli and 
Antimicrobial susceptibility and double-disk synergy testing
Antimicrobial susceptibilities to cefotaxime, ceftazidime, cefepime, and aztreonam were tested by the disk diffusion method [16] by using SPSS statistics (version 23, IBM Corp., Armonk, NY, USA) and the significance (P) was indicated by using asterisks: **P＜0.01; *P＜0.05.
DNA manipulation and PCR
Total DNA was extracted by using MG Cell genomic DNA extraction kit (MGmed Inc., Seoul, South Korea) and, by using the extracted total DNA, PCR and sequencing were carried out to detect the genes for carbapenemases, i.e., blaKPC, blaNDM, blaIMP, blaVIM, blaGES, and blaOXA-48 [13] ; ESBLs, i.e. for blaCTX-M-1-like, blaCTX-M-9-like, and blaCTX-M-25-like; and plasmid-mediated AmpCs, i.e., blaCMY, blaDHA, and blaACC [14, 15] .
Statistical analysis
Differences existed between groups were calculated by chi-square or t-test [16] 6 mm) were greater in E. coli than in K. pneumoniae (Fig. 1A) .
CTX-M-type ESBL-producing E. coli and K. pneumoniae
Of the DDST-positive isolates, 95.4% (269/282) E. coli and 86.4% (76/88) K. pneumoniae were identified as CTX-M ESBL producers by PCR (Table 2 ). In both enterobacterial species, the group 1 CTX-M ESBL was more identified than the group 9:
146:113 in E. coli and 65:10 in K. pneumoniae. Ten E. coli and one K. pneumoniae co-produced both groups of CTX-M ESBL.
Co-carrying β-lactamase genes were identified in 6.7% 
Resistance phenotypes conferred by CTX-M ESBL
By the group of CTX-M enzymes, the zone diameters by the disks containing extended-spectrum cephalosporins or monobactams were smaller in group 1 than those in group 9 exhibiting the median values of 6 mm vs. 9 mm for cefotaxime, 14 mm vs. 22 mm for ceftazidime, 13 mm vs. 17 mm for cefepime, and 9 mm vs. 17 mm for aztreonam (Fig. 1C) . The zone diameters of 11 Enterobacteriaceae producing both group 1 and group 9 CTX-M ESBLs were close to those in group 1 CTX-M ESBL producers rather than those in the group 9 producer: median values at 6 mm for cefotaxime, 12 mm for ceftazidime, 11 mm for cefepime, and 9 mm for aztreonam. Co-production of either SHV ESBL or AmpC in K. pneumoniae retained the inhibition zone diameters: median values of zone diameter at 9 mm for cefotaxime, 10 mm for ceftazidime, 14 mm for cefepime, and 6 mm for aztreonam in SHV ESBL co-producers and 9 mm for The SC was calculated by dividing the enlarged zone diameter near the clavulanic acid disk by inhibition zone diameter of each drug. The correlation coefficient (r) was calculated using Pearson's correlation [16] by the parametric method using SPSS statistics and the significance (P) was determined by a two-tailed method using the correlation value and the sample size. Each dot indicates one strain, gray triangles and black dots indicate strains producing CTX-M group 1 and group 9, respectively. cefotaxime, 11 mm for ceftazidime, 14 mm for cefepime, and 6 mm for aztreonam in AmpC co-producers. The KPC-2 carbapenemase co-producer exhibited the reduced inhibition zones, 6 mm for cefotaxime, 9 mm for ceftazidime, 9 mm for cefepime, and 6 mm for aztreonam.
The synergistic effect with CA was evaluated using SC values ( Fig. 1B-D) 
DISCUSSION
Continuing increase in CTX-M-type ESBL-producing
Enterobacteriaceae, mainly led by the predominant CTX-M-15
of group 1 and CTX-M-14 of group 9 [17] , triggers more usage of last options for the treatment resulting in vicious antimicrobial resistance. In South Korea, cefotaxime resistance reached at 38% for E. coli and at 35% for K. pneumoniae clinical isolates in 2015 [18] and it was associated with dominance of both CTX-M-15 and -14 since the mid-2010s [19] . The enterobacterial blood isolate collection of seven-month-period in 2017 presented cefotaxime resistance rates at 31.6% for E. coli and at 24.0% for K. pneumoniae, which were less than those in 2015, probably due to the differed specimens and surveillance systems. The dominant type of group 1 was CTX-M-15 (78.4%) and that of group 9 was CTX-M-14 (50.0%).
The rate of human carriages of CTX-M producers are increasing [17] and the dissemination is issuing not only among human beings but also for animals [20, 21] and environments [22] . The resistance rates for cefotaxime (5.0%) and cefepime (1.4%) in E. coli from food animals [23] and in Enterobacteriaceae from edible vegetables (10.1% for cefotaxime and 1.1% for cefepime) [24] were comparably lower than those in clinical isolates. Inhibition zone sizes of the tested drugs were always smaller for the group 1 CTX-M ESBL than those for the group 9 confirming that the group 1 enzyme confers higher level of resistance to the drugs than the group 9 [25] . As well, the SCs, indicating the hydrolytic activity inhibited by CA, were greater for the tested drugs in the group 1 CTX-M ESBL compared to those in the group 9 supporting that the group 1 enzymes hydrolyzed more the drugs than those belonging to the group 9. It is noteworthy that the ceftazidime SC in group 9 CTX-M ESBL is close to 1, agreeing the point that ceftazidime resistance, which has been used in practice as an indicator of ESBL producers, frequently leads to fail recognizing CTX-M-producers [6] . The higher prevalence of CTX-M ESBLs, which is the case of this study, may elevate the false-negative error rates [26] .
Masked synergistic activity with CA by induced AmpC [10] was not observed in this study, doubtlessly because intrinsic notypes are going to be further studied.
